EGQ0 Stock Overview
INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
INOVIQ Ltd Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.33 |
52 Week High | AU$0.56 |
52 Week Low | AU$0.27 |
Beta | 2.2 |
1 Month Change | -26.55% |
3 Month Change | -17.00% |
1 Year Change | 9.93% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -50.21% |
Recent News & Updates
Recent updates
Shareholder Returns
EGQ0 | DE Healthcare | DE Market | |
---|---|---|---|
7D | 0% | -1.1% | 1.4% |
1Y | 9.9% | 0.2% | 7.5% |
Return vs Industry: EGQ0 exceeded the German Healthcare industry which returned -1.4% over the past year.
Return vs Market: EGQ0 exceeded the German Market which returned 5.5% over the past year.
Price Volatility
EGQ0 volatility | |
---|---|
EGQ0 Average Weekly Movement | 8.9% |
Healthcare Industry Average Movement | 5.2% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.2% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: EGQ0's share price has been volatile over the past 3 months.
Volatility Over Time: EGQ0's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1983 | n/a | Leearne Hinch | https://www.inoviq.com |
INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample. Its cancer diagnostic pipeline includes blood tests in development for ovarian, breast, and other cancers.
INOVIQ Ltd Fundamentals Summary
EGQ0 fundamental statistics | |
---|---|
Market cap | €31.61m |
Earnings (TTM) | -€3.92m |
Revenue (TTM) | €955.15k |
33.1x
P/S Ratio-8.1x
P/E RatioIs EGQ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EGQ0 income statement (TTM) | |
---|---|
Revenue | AU$1.58m |
Cost of Revenue | AU$3.26m |
Gross Profit | -AU$1.68m |
Other Expenses | AU$4.83m |
Earnings | -AU$6.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.071 |
Gross Margin | -105.79% |
Net Profit Margin | -410.78% |
Debt/Equity Ratio | 0% |
How did EGQ0 perform over the long term?
See historical performance and comparison